Your browser doesn't support javascript.
Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.
Khoury, Maroun; Cuenca, Jimena; Cruz, Fernanda F; Figueroa, Fernando E; Rocco, Patricia R M; Weiss, Daniel J.
  • Khoury M; Laboratory of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Santiago, Chile mkhoury@uandes.cl.
  • Cuenca J; Cells for Cells and consorcio Regenero, Chilean Consortium for Regenerative Medicine, Santiago, Chile.
  • Cruz FF; M. Khoury and D.J. Weiss contributed equally as lead authors of the study.
  • Figueroa FE; Laboratory of Nano-Regenerative Medicine, Faculty of Medicine, Universidad de los Andes, Santiago, Chile.
  • Rocco PRM; Cells for Cells and consorcio Regenero, Chilean Consortium for Regenerative Medicine, Santiago, Chile.
  • Weiss DJ; Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Eur Respir J ; 55(6)2020 06.
Article in English | MEDLINE | ID: covidwho-42121
ABSTRACT
The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced lung injury; however, there are no available data in models of coronavirus respiratory infection.There is a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies and targeted patient populations. To provide a rational strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. This review presents these, along with consideration of current clinical investigations.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Respiratory Distress Syndrome / Culture Media, Conditioned / Coronavirus Infections / Mesenchymal Stem Cell Transplantation / Influenza, Human / Lung Injury Type of study: Prognostic study Limits: Animals / Humans Language: English Year: 2020 Document Type: Article Affiliation country: 13993003.00858-2020

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Respiratory Distress Syndrome / Culture Media, Conditioned / Coronavirus Infections / Mesenchymal Stem Cell Transplantation / Influenza, Human / Lung Injury Type of study: Prognostic study Limits: Animals / Humans Language: English Year: 2020 Document Type: Article Affiliation country: 13993003.00858-2020